Innovative technology represents a shift in Alzheimer’s management from symptom relief to treating the underlying condition
Essentia Health is bringing a groundbreaking tool in early detection of Alzheimer’s disease to the Northland. A new diagnostic test that detects amyloid plaque – abnormal protein deposits in the brain that can disrupt cognitive function and a defining feature of Alzheimer’s – represents a major breakthrough in care for a disease that affects more than 7 million Americans.. Regionally, this new test is only offered at Essentia’s downtown Duluth campus.
This innovative service provides local patients with faster, less-invasive access to critical diagnostics, eliminating long waits and extensive travel previously required for similar testing.
“This represents a major leap forward in Alzheimer’s care for our community,” said Dr. Stephen Rostad, a neurologist at Essentia. “By detecting amyloid plaques early, we can confirm eligibility for breakthrough treatments that target and reduce these deposits, potentially slowing the progression of cognitive decline. It’s about giving patients and families hope through timely intervention.”
This new scan uses existing PET and CT technology, paired with a safe radioactive tracer called Amyvid. Once injected, the Amyvid binds to these plaques and highlights them during imaging.
The procedure is quick and easy: After a 40-minute circulation period, the scan itself takes just 10 minutes, with the entire visit lasting less than an hour.
If the imaging detects elevated levels of amyloid plaque, FDA-approved therapies are introduced. These infusions work to break up amyloid plaques; infusion regimens vary depending on scan results. Essentia Health has already performed several scans since initiating the program in July. Alzheimer’s often goes undiagnosed until symptoms are advanced. Early detection via amyloid PET/CT allows for personalized treatment plans, improving quality of life and reducing the burden on families.
This technology signals a shift in Alzheimer’s management from symptom relief to disease modification. As research evolves, treatments like these could delay onset or even prevent severe progression, transforming Alzheimer’s from a devastating diagnosis into a manageable condition. Essentia’s investment in this service will help position the region at the forefront of these advancements.
